Phase II Study of Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall Survival
1 year survival
No
Vassilis Georgoulias, MD
Principal Investigator
University Hospital of Crete, Dep of Medical Oncology
Greece: National Organization of Medicines
CT/06.13
NCT00564720
December 2006
March 2011
Name | Location |
---|